10/09/2023
cover
Dear Dr Kilasonia,
Thank you for publishing your article in The Lancet Rheumatology . Director zeng completed the Rights and Access Form for your article A Phase 3, Randomised, Multicentre, Double-Blind, Active-Controlled Clinical Trial to Compare BAT1806/BIIB800, a Proposed Tocilizumab Biosimilar, with Tocilizumab Reference in Subjects with Moderate to Severe Rheumatoid Arthritis with an Inadequate Respo… on September 10, 2023.
The Order Summary is attached to this email. A copy of the Order Summary is also sent to all co-authors for whom we have contact details.
If you have any questions, please do not hesitate to contact us. To help us assist you, please quote our article reference LANRHE864 in all correspondence.
Now that your article has been accepted, you will want to maximize the impact of your work. Elsevier facilitates and encourages authors to share their article responsibly. To learn about the many ways in which you can share your article whilst respecting copyright, visit: www.elsevier.com/sharing-articles.
Kind regards,
The Lancet Rheumatology
Image Seve
Make a bigger impact and get noticed by sharing your article using Share Link; monitor with My Research Dashboard and article level metrics.
